A phase II, multicenter, randomized, double-blind, placebo-controlled parallel group, dose finding study evaluating the safety and efficacy of Infliximab administration in symptomatic subjects with moderate to severe chronic obstructive pulmonary disease (COPD).

A randomized, double-blind, placebo-controlled, parallel group trial assessing the rate of decline of lung function with Tiotropium 18 mg inhalation capsule once daily in patients with chronic obstructive pulmonary disease (COPD).

A comparison of Iptratropium bromide/Salbutamol delivered by the Respimat® inhaler to Iptratropium bromide Respimat®, Combivent® inhalation aerosol and placebo of each formulation in a 12-week, double-blind, safety and efficacy study in adults with

A randomized, double-blind, double-dummy, placebo-controlled crossover efficacy and saftety comparison of 4-week treatment periods of two doses [5 mg (2 actuations of 2.5 mg) and 10 mg (2 actuations of 5 mg)] of Tiotropium inhalation solution delivered by the Respimatmg) delivered by the HandiHaler

A randomized, partly blinded, multicenter, parallel study comparing the efficacy and safety of Pulmicort Respules® (Budesonide inhalation suspension) at 0.5 mg qD, 1.0 mg qD, 1.0 mg BID, 2.0 mg BID and Pulmicort Turbuhaler® (Budesonide) at 400 mg BID in adolescents (12 years of age and older) and adults with moderate to severe asthma.  

A multicenter, randomized, double-blind, parallel group, placebo-controlled study to investigate the long-term effects of Salmeterol/fluticasone propionate (SEREVENT /VIANI /ADVAIR) 50/500 µg BID and Fluticasone proprionate 500 µg BID, all delivered bia the Diskus/Accuhaler inhaler, on the survival of subjects with

A 24 week, placebo-controlled, randomized, parallel group study comparing Roflumilast 500 mg daily vs placebo on pulmonary function and respiratory symptoms in patients with chronic obstructive pulmonary disease (COPD).

An 8 Week, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy of Tiotropium Inhalation Capsules In Patients of African Descent with Chronic Obstructive Pulmonary Disease.